-
Luke's Most Recent
Search Results
240 results for abv
Strong Buy for AbbVie (ABBV) This Week
At $118.94, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Take This One Step to Avoid AI’s Extinction Event
AI is not a trend. It’s not even a wave. It’s a mass extinction event for outdated business models. The kind of event that permanently…
Why TradeSmith GPT Is Rewriting the Rules of Trading
On Tuesday, I introduced you to TradeSmithGPT – a revolutionary AI-powered trading system that I believe could change the game for everyday investors. But as…
What Gold Knows That Congress Keeps Ignoring
The U.S. has started to probe the outer limits of debt accumulation… and the gold market is watching. This precious metal deserves an allocation in every…
AbbVie (ABBV) a Buy on Healthy Earnings Momentum
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no…
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this…
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock’s current Portfolio Grader score places…
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $117.98
At $117.98, AbbVie (ABBV) a Strong Buy based on the latest SEC filings, and comparative pricing of its shares.
AbbVie Inc: ABBV Stock Is a Prescription for Profits
Investors and traders should be positioning themselves in AbbVie stock. This trade on ABBV will help you limit earnings volatility while allowing you to enjoy…
AbbVie Inc (ABBV) Is About to Steamroll the Competition
Good news for AbbVie (ABBV) shareholders: The pharmaceutical company just entered the Hepatitis C. market, while reinforcing its position in the psoriasis area. Given ABBV’s…
Trade of the Day: AbbVie Inc. (NYSE:ABBV)
AbbVie has a great opportunity for growth in developing and commercialize BioArctic’s treatment platform for neurodegenerative diseases.
Hold Recommendation for AbbVie (ABBV) Stock Kept
Currently, AbbVie Inc (NYSE:ABBV) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. This represents no change…
What Grocery Shopping and This $15T Opportunity Have in Common
Every day gives us a new distraction in the markets, making it impossible to keep track of what’s important. Meanwhile, the most crucial invention of…
ABBV Stock Slips as AbbVie Faces Opioid Lawsuits
AbbVie’s quarterly results were roughly in line with Wall Street’s expectations, but ABBV stock still slipped in early trading.
AbbVie Inc (ABBV) Earnings: 12 Things to Know
AbbVie (ABBV) has released its earnings report for the third quarter of 2017 and ‘InvestorPlace’ has a few things to know about it.
Superior Earnings Momentum Keeps AbbVie (ABBV) a Buy
AbbVie Inc (NYSE:ABBV) is one of 345 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health…
JD.com Stock Should Be Able to Soar Above $50
JD stock has been troubled for several years now, but the long-term growth outlook is steadily improving – thanks to global retail expansion, a tailwind…
Biggest Movers in Services Stocks Now – ARE CCO AVB AIV
Services stocks finished down broadly on Wall Street on Monday, with the sector seeing an overall decline of 0.5%.
AbbVie Inc (ABBV) Has More Blockbusters on the Horizon
AbbVie (ABBV) isn’t just resting on the success of Humira; this major pharmaceutical firm is building for a long, strong future.
ABBV: AbbVie Beats Street on Soaring Humira Sales
Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher.
From Middle East Tensions to Market Euphoria: Why AI Stocks Keep Winning
Even with potential near-term bumps, it appears the broader direction of this market is tilted higher… especially for AI stocks.
7 – 10 of 240 results
